| Nivolumab for recurrent squamous-cell carcinoma of the head and neck RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... New England Journal of Medicine 375 (19), 1856-1867, 2016 | 4538 | 2016 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 723 | 2018 |
| High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ... Cancer discovery 7 (6), 586-595, 2017 | 660 | 2017 |
| Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma E Saâda-Bouzid, C Defaucheux, A Karabajakian, VP Coloma, V Servois, ... Annals of Oncology 28 (7), 1605-1611, 2017 | 585 | 2017 |
| Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ... Journal of Clinical Oncology 35 (36), 4050-4056, 2017 | 412 | 2017 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 398 | 2017 |
| Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study RL Ferris, R Haddad, C Even, M Tahara, M Dvorkin, TE Ciuleanu, ... Annals of Oncology 31 (7), 942-950, 2020 | 282 | 2020 |
| Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1–low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial LL Siu, C Even, R Mesía, E Remenar, A Daste, JP Delord, J Krauss, ... JAMA oncology 5 (2), 195-203, 2019 | 262 | 2019 |
| Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with≥ 25% tumour cell PD-L1 expression who … DP Zandberg, AP Algazi, A Jimeno, JS Good, J Fayette, N Bouganim, ... European journal of cancer 107, 142-152, 2019 | 229 | 2019 |
| Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use RL Ferris, L Licitra, J Fayette, C Even, G Blumenschein Jr, KJ Harrington, ... Clinical Cancer Research 25 (17), 5221-5230, 2019 | 137 | 2019 |
| Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck K Saleh, A Daste, N Martin, E Pons-Tostivint, A Auperin, ... European Journal of Cancer 121, 123-129, 2019 | 130 | 2019 |
| Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell … J Guigay, A Aupérin, J Fayette, E Saada-Bouzid, C Lafond, M Taberna, ... The Lancet Oncology 22 (4), 463-475, 2021 | 124 | 2021 |
| Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations AL Ho, I Brana, R Haddad, J Bauman, K Bible, S Oosting, DJ Wong, ... Journal of Clinical Oncology 39 (17), 1856, 2021 | 120 | 2021 |
| Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group A Le Cesne, I Ray-Coquard, F Duffaud, C Chevreau, N Penel, BB Nguyen, ... European Journal of Cancer 51 (6), 742-750, 2015 | 105 | 2015 |
| Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study C Even, S Bastuji-Garin, Y Hicheri, C Pautas, F Botterel, S Maury, ... haematologica 96 (2), 337, 2011 | 86 | 2011 |
| CheckMate 141: 1‐year update and subgroup analysis of nivolumab as first‐line therapy in patients with recurrent/metastatic head and neck cancer ML Gillison, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... The oncologist 23 (9), 1079-1082, 2018 | 84 | 2018 |
| TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma J Adam, E Louvet, T Sourisseau, N Dorvault, M Bernard, E Maingot, ... ESMO open 3 (1), e000257, 2018 | 82 | 2018 |
| TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Guigay, J Fayette, R Mesia, C Lafond, E Saada-Bouzid, L Geoffrois, ... Journal of Clinical Oncology 37 (15_suppl), 6002-6002, 2019 | 77 | 2019 |
| Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN … RL Ferris, GR Blumenschein, J Fayette, J Guigay, AD Colevas, LF Licitra, ... Journal of Clinical Oncology 34 (15_suppl), 6009-6009, 2016 | 68 | 2016 |
| Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis P Blanchard, F Belkhir, S Temam, C El Khoury, F De Felice, O Casiraghi, ... European Archives of Oto-Rhino-Laryngology 274, 1683-1690, 2017 | 60 | 2017 |
